Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 1.00 |
| ▸ | PDE2A | O00408 | 1/20 | 1.00 |
| ▸ | PDE1A | P54750 | 1/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 1/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27383537 | 0.99 | PDE5A (0.98) | PDE5APDE2APDE1APDE1BPDE1C | |
| SCHEMBL7497751 | 0.94 | PDE5A (1.00) | PDE5APDE2APDE1APDE1BPDE1C | |
| SCHEMBL7497761 | 0.90 | PDE5A (1.00) | PDE5APDE2APDE1APDE1BPDE1C | |
| SCHEMBL27357129 | 0.88 | PDE5A (0.89) | PDE5APDE2APDE1APDE1BPDE1C | |
| SCHEMBL7496280 | 0.87 | PDE5A (0.76) | PDE5APDE2APDE1APDE1BPDE1C | |
| SCHEMBL7500002 | 0.87 | PDE5A (0.76) | PDE5APDE2APDE1APDE1BPDE1C | |
| SCHEMBL7500246 | 0.87 | PDE5A (0.76) | PDE5APDE2APDE1APDE1BPDE1C | |
| SCHEMBL10267709 | 0.87 | PDE5A (0.76) | PDE5APDE2APDE1APDE1BPDE1C | |
| SCHEMBL7504986 | 0.86 | PDE5A (1.00) | PDE5APDE2APDE1APDE1BPDE1C | |
| SCHEMBL27355392 | 0.85 | PDE5A (1.00) | PDE5APDE2APDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106061-B2 | Use of phosphodiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2012-01-31 | — | — | US | claimed |
| US-20030199517-A1 | Comprises 2-(2-propoxyphenyl)-8-azapurin-6-one (zaprinast); for treatment of benign prostatic hyperplasia and urination disorders | WOLF-GEORG FORSSMANN | 2003-10-23 | — | — | US | claimed |
| US-20020025969-A1 | Genign prostatic hyperolasia | ERFINDERGEMEINSCHAFT UROPEP GBR (DE) | 2002-02-28 | — | — | US | claimed |
| US-8791124-B2 | Use of phosphordiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791124-B2 | Use of phosphordiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120172365-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | UROPEP BIOTECH GBR | 2012-07-05 | — | — | US | disclosed |
| US-20120172365-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | UROPEP BIOTECH GBR | 2012-07-05 | — | — | US | disclosed |
| US-20120172365-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | UROPEP BIOTECH GBR | 2012-07-05 | — | — | US | disclosed |
| US-8106061-B2 | Use of phosphodiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2012-01-31 | — | — | US | disclosed |
| US-8106061-B2 | Use of phosphodiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2012-01-31 | — | — | US | disclosed |
| US-8106061-B2 | Use of phosphodiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2012-01-31 | — | — | US | disclosed |
| EP-0607439-B1 | NITROGENOUS HETEROCYCLIC COMPOUND | EISAI CO LTD (JP) | 2002-01-09 | — | — | EP | disclosed |
| US-6046206-A | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives | CELL PATHWAYS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| WO-1999002161-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | FORSSMANN WOLF GEORG (DE) | 1999-01-21 | — | — | WO | disclosed |
| WO-1999002161-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | FORSSMANN WOLF GEORG (DE) | 1999-01-21 | — | — | WO | disclosed |
| US-5801180-A | ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | EISAI CO., LTD. (JP) | 1998-09-01 | — | — | US | disclosed |
| US-5693652-A | Benzimidazoles for ischemic heart conditions | EISAI CO., LTD. (JP) | 1997-12-02 | — | — | US | disclosed |
| US-5576322-A | Anti-ischemic 2,4-diaminoquinazolines | EISAI CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0607439-A1 | NITROGENOUS HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
| CN-1071164-A | Nitrogen-containing heterocycle compound | EISAI CO LTD (JP) | 1993-04-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172365-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | PDE5A, PDE7A, PDE12 | PDE5A 1/4885PDE2A 8/4885PDE1A 15/4885 |
| US-20030199517-A1 | Comprises 2-(2-propoxyphenyl)-8-azapurin-6-one (zaprinast); for treatment of benign prostatic hyperplasia and urination disorders | PDE12, PDE5A, QDPR | PDE5A 2/4885PDE2A 4/4885PDE1A 25/4885 |
| US-20020025969-A1 | Genign prostatic hyperolasia | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE2A 3/4885PDE1A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.